Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $27.3052W HIGH $73.75
Volume
1.61 M
Value Traded
145.71 M
Short % Float
6.04%
+2.81%Week
+10.12%1 Month
-8.47%3 Month
+38.47%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.61 B
EPS (TTM)
1.85
P/E Ratio
34.46
Ent. Value
14.29 B
Total Shares
197.79 M
Float Shares
168.56 M
Insiders
14.81%
Institutions
92.24%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BTSG Catalyst Timeline
Dated clinical, regulatory and corporate events for BrightSpring Health Services, Inc. Common Stock
Past FDA Catalysts and PDUFA Decisions
How BTSG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
BrightSpring Health Services, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every BTSG program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Greenwell Scott A.Officer (President, PharMerica) | Option | 11,973 46,345 held | $22.27 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BTSG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.5 % (-40 %) | 38.36 M | 550.00 K | -56% ( -700.00 K) |
BTSG Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BTSG ranks across every disease it competes in
Competitive Position is a premium feature
See how BTSG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBTSG News
-BTSG
Oct 1, 2026BrightSpring Health Services, Inc. to Announce Third Quarter 2026 Financial Results on October 30, 2026
BrightSpring Health Services, Inc. will release its third quarter 2026 financial results on October 30, 2026. The announcement will precede an earnings conference call scheduled for 8:30 a.m. ET on the same day. Interested participants can register for the call and access a live and archived webcast on the company's investor relations website.
Read more →-BTSG
Jul 31, 2026▼ -18.1%on this news
BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
BrightSpring Health Services reported strong financial results for Q2 2026, with net revenue rising to $3,873 million, a 23.0% increase from the previous year. The company also announced an increase in its full year guidance for revenue and Adjusted EBITDA, reflecting a positive outlook for continued growth. CEO Jon Rousseau emphasized the company's commitment to quality care and operational excellence.
Read more →-BTSG
Jul 8, 2026BrightSpring Health Services, Inc. to Announce Second Quarter 2026 Financial Results on July 31, 2026
BrightSpring Health Services, Inc. will release its second quarter 2026 financial results on July 31, 2026. The announcement will precede an earnings conference call scheduled for 8:30 a.m. ET. The company offers comprehensive health solutions and has shown strong performance metrics across its services.
Read more →-BTSG
Jun 12, 2026BrightSpring Health Services, Inc. Welcomes Dr. Nigam H. Shah to Board of Directors
BrightSpring Health Services has appointed Dr. Nigam H. Shah to its Board of Directors. Dr. Shah, a prominent figure in healthcare technology and AI, will also serve on the Quality and Compliance Committee. His extensive background in data science and healthcare is expected to contribute significantly to the company's mission of improving patient outcomes.
Read more →-BTSG
Jun 4, 2026▼ -5.7%on this newsshared move
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
BrightSpring Health Services has priced a secondary offering of 15 million shares at $58.75 each, with proceeds going to selling stockholders. Concurrently, the company plans to repurchase 1,026,694 shares from the underwriter at the same price. The offering is expected to close on June 5, 2026, subject to customary conditions.
Read more →-BTSG
May 26, 2026BrightSpring Awards Brighter Futures Scholarship and Hospice Nursing Scholarship to Support Five Students’ Academic Journeys
BrightSpring Health Services has awarded the 2026 Brighter Futures Scholarship to Derek Pearson and Hospice Nursing Scholarships to four students. This initiative aims to support under-reached students pursuing careers in healthcare, particularly in hospice care. The scholarships reflect BrightSpring's commitment to enhancing access to education and strengthening the healthcare workforce.
Read more →-BTSG
May 1, 2026▲ +9.6%on this newsshared move
BrightSpring Health Services, Inc. Reports First Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
BrightSpring Health Services, Inc. reported strong financial results for Q1 2026, with net revenue increasing by 25.6% to $3.614 billion and a net income of $74 million, up from $9 million in Q1 2025. The company also raised its full-year 2026 guidance for revenue and Adjusted EBITDA, reflecting confidence in its operational strategies. The divestiture of its Community Living business contributed positively to its financial metrics.
Read more →-BTSG
Apr 21, 2026Jon Rousseau Named Entrepreneur Of The Year® 2026 East Central finalist by EY US
Jon Rousseau, President and CEO of BrightSpring Health Services, has been named a finalist for the Entrepreneur Of The Year 2026 East Central Award by EY US. This recognition celebrates entrepreneurs who drive economic growth and innovation. Rousseau's leadership and dedication to quality care have been key factors in his selection among 32 finalists from various industries.
Read more →-BTSG
Mar 31, 2026BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita
BrightSpring Health Services has completed the sale of ResCare Community Living to Sevita. This strategic divestiture aims to enhance care quality and operational stability for individuals with disabilities. Both companies expressed commitment to their missions and the continuity of care during the transition, which was carefully managed to prioritize workforce stability and regulatory compliance.
Read more →-BTSG
Feb 27, 2026BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
BrightSpring Health Services, Inc. reported its financial results for Q4 and the full year 2025, highlighting strong performance driven by demand for its services. The company provided guidance for 2026, indicating expectations for revenue and Adjusted EBITDA growth. CEO Jon Rousseau emphasized the focus on delivering high-quality patient care.
Read more →-BTSG
Feb 18, 2026▲ +7%on this news
BrightSpring Health Services, Inc. to Host Investor Day on March 17, 2026
BrightSpring Health Services, Inc. will host an Investor Day on March 17, 2026, at 8:30 a.m. ET. The event will include presentations from the leadership team and Q&A sessions. Attendance is by invitation only, and a webcast will be available for broader access.
Read more →-BTSG
Dec 2, 2025The 2026 BrightSpring Brighter Futures and Hospice Nursing Scholarships Now Open
BrightSpring has announced the opening of applications for the 2026 Brighter Futures and Hospice Nursing Scholarships. The Brighter Futures Scholarship offers $10,000 per year for students demonstrating financial need and maintaining a GPA of at least 3.0. The Hospice Nursing Scholarship awards four $5,000 scholarships for students enrolled in nursing programs with a focus on hospice care.
Read more →-BTSG
Nov 13, 2025▼ -5.6%on this news
Signature Advantage (HMO SNP) Announces Brand Change to Abilis Health Plan
Signature Advantage (HMO SNP) is rebranding to Abilis Health Plan, maintaining its commitment to high-quality healthcare. The transition involves only a change in name, logo, and brand identity, while all other plan details remain unchanged. Members can access updated resources on both the Signature Advantage and Abilis Health Plan websites.
Read more →-BTSG
Oct 28, 2025BrightSpring Health Services, Inc. Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance LOUISVILLE, Ky.
BrightSpring Health Services, Inc. reported a robust financial performance for the third quarter of 2025, achieving a revenue of $3,334 million, a significant increase of 28.2% from the previous year. The company's net income turned positive at $37.5 million compared to a loss in the same quarter of the prior year. Additionally, BrightSpring raised its full-year revenue guidance to between $12,500 million and $12,800 million. The company also reiterated its adjusted EBITDA guidance, indicating strong operational progress despite competitive challenges.
Read more →-BTSG
Oct 20, 2025BrightSpring Health Services, Inc. Reports Preliminary Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
BrightSpring Health Services, Inc. reported preliminary financial results for the third quarter of 2025, showing significant growth compared to the same period last year. The company achieved approximately $3,334 million in revenue, a 28.2% increase, and a net income of approximately $37.5 million, a turnaround from a loss in the previous year. Adjusted EBITDA also rose by 37.2% to about $160 million. Furthermore, BrightSpring has increased its revenue and adjusted EBITDA guidance for the full year 2025, signaling continued positive performance expectations.
Read more →-BTSG
Aug 1, 2025BrightSpring Health Services, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
BrightSpring Health Services, Inc. reported strong financial results for the second quarter of 2025, with net revenue increasing by 29.1% to $3,148 million compared to the previous year. Adjusted EBITDA also showed significant growth, climbing 28.8% to $143 million. The company announced an increase in its full year 2025 guidance for revenue and adjusted EBITDA, reflecting a positive outlook for continued growth. Additionally, the planned divestiture of the Community Living business is expected to take place in Q4 2025, which may impact future results.
Read more →-BTSG
Jun 10, 2025▼ -6.8%on this news
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion analyzes our financial condition and results of operations and should be read in conjunction with our
The article discusses the financial performance and strategic plans of BrightSpring (BTSG) for the fiscal year 2024 compared to 2023. The company reported a substantial revenue increase of 31%, driven primarily by its Pharmacy Solutions segment. It plans to divest its Community Living business to streamline operations and enhance focus on core services. Despite achieving positive financial metrics, such as reduced net loss and increased adjusted EBITDA, the company acknowledges inherent risks in its business environment.
Read more →-BTSG
May 2, 2025▲ +16.6%on this news· ran to +29% by day 3shared move
BrightSpring Health Services, Inc. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
BrightSpring Health Services, Inc. reported strong financial results for the first quarter of 2025, showing significant improvements over the same period last year. Net revenue climbed to $2.878 billion, up 25.9%, while the company achieved a net income of $9.2 million, a recovery from a loss of $56.0 million in Q1 2024. The company has also increased its full-year guidance for revenue and adjusted EBITDA, reflecting confidence in ongoing growth. The planned divestiture of the Community Living business remains on course.
Read more →-BTSG
Mar 6, 2025▼ -6.3%on this news
BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Increases Full Year 2025 Guidance
BrightSpring Health Services, Inc. reported strong financial results for the fourth quarter and full year 2024, achieving a 28.6% increase in net revenue and a net income of $15.4 million, a significant improvement from the previous year's loss. The company also raised its revenue and Adjusted EBITDA guidance for 2025, focusing on growth while planning to streamline operations after the divestiture of its Community Living business. Despite a net loss for the full year, the overall outlook remains optimistic as BrightSpring aims to enhance its service solutions for complex health populations.
Read more →About BrightSpring Health Services, Inc. Common Stock
Headquarters805 N. WHITTINGTON PARKWAY, LOUISVILLE, KY, 40222
BIOPHARMAWATCH ELITE PLUS
Trade the next BTSG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime